The effect of propranolol on plasma dopamine-beta-hydroxylase activity and triiodothyronine was investigated in twelve subjects with Graves' disease. Plasma DBH activity, serum triiodothyronine and thyroxine were determined beforehand and electrocardiograms were recorded on the same days as the blood samples were taken. Propranolol administration was associated with clinical amelioration in blood pressure and ECG. There was a positive and significant correlation between changes in DBH activity and triiodothyronine caused by propranolol.
It is well established that beta-adrenergic blocking agents modify some of the manifestations of the hyperthyroid state in man, but the precise mode of action of these agents in hyperthyroidism is not well understood. Recently, it has been reported that propranolol treatment lowers plasma triiodothyronine (T3) in hyperthyroid patients (Wiersinga and Touber, 1977; Verhoeveri et al., 1977) and in hypothyroid patients on L-thyroxine substitution therapy (Wiersinga and Touber, 1977) .
On the other hand, although serum dopamine-beta-hydroxylase (DBH) activity is depressed in hyperthyroid patients (North and Spaulding, 1974; Nishizawa et al., 1974) and there may be a relationship between serum DBH activity and thyorid suppressibility in hyperthyroidism (Tanaka et al., 1979) , the effect of the beta adrenocepter blocking agent, propranolol, on the enzyme activity has not been investigated in Graves' disease to our knowledge.
It is also not clear whether the decrease in plasma T3 during propranolol medication is dependent on the functional status of the beta-adrenergic system.
Since beta-blockers have been thought to control only some of the clinical features of hyperthyroidism at present (McDevitt, 1976) , it is necessary to evaluate the changes in plasma DBH activity and T3 in conjunction with the peripheral manifestations of hyperthyroidism.
We therefore studied the effect of propranolol on the plasma levels of T4, T3 DBH activity and the manifestations of the hyperthyroid state in man.
Materials and Methods
Twelve subjects for this study (eleven females and one male, varying in age from 13 to 42 years, Table 2 . Effect of propranolol on the R-R, P-R, and Q-T intervals, QRS width, Q-Tc derived from the Bazzett formula and the height of the T wave in patients with hyperthyroidism.
All data; Mean •} SEM NS=not significant Table 3 . Effect of propranolol on serum T3 and DBH activity in patients with Graves' disease.
*Before propranolol treatment **During 60 mg propranolol administration ***Differences between before and during propranolol administration . f=females, m=male corrected for the heart rate, the Q-Tc was similar before and during beta-blocking agents.
As shown in Fig. 1 , there was a highly linear correlation (r=0.797, P< 0.001) between the DBH and the triiodothyronine response to 60 mg propranolol. These changes are also shown in Table 3 . However, the plasma DBH response to propranolol did not correlate with the changes in heart rate, blood pressure and ECG. Moreover, the response of serum triiodothyronine during propranolol had also no correlation with the desirable modification of clinical manifestations. 
Discussion
Considering the recommended does for moderate thyrotoxicosis (Landsberg, 1977) and the relative low body weight of our patients, 60 mg propranolol per day was sufficient to result in significant clinical benefit. In fact, our results showed significant clinical relief in heart rate, blood pressure and ECG, but there was no significant change in the mean values for triiodothyronine and DBH activity during propranolol treatment 60 mg of propranolol may be a sufficent does for controlling symptoms and signs but insufficient for reducing triiodothyronine which was reported recently with higher doses of propranolol (Wiersinga and Touber, 1977; Verhoeven et al., 1977) The beneficial effect of 60 mg propranolol without lowering T3 suggests that there may be another explanation, such as the effect of propranolol on the free T3 level (Kristensen et al., 1978) producing a favorable effect in propranolol therapy for hyperthyroidism.
The changes in DBH activity and triiodothyronine during propranolol treatment varied from patient to patient and this might be responsible for considerable (up to 20-hold) individual variation in patients receiving the same oral does (Evans and Shand, 1973) . In some cases (case 1, 3, 9 in Table 3 ) the changes in DBH activity and T3 levels are opposite to each other and this may be due to some other factors affecting serum DBH activity such as genetic factors, growth and development, circadian rhythm, stress. Of great interest was the positive significant correlation between changes in DBH activity and triiodothyron- 
